Results 151 to 160 of about 26,548 (293)

Corticotropin releasing hormone antagonist does not prevent adrenalectomy-induced apoptosis in the dentate gyrus of the rat hippocampus. [PDF]

, 1998
Adrenalectomy in the mature rat leads to death of granule cells in the dentate gyrus of the hippocampal formation. The mechanisms underlying this cell death have not been fully clarified: It has been considered that the granule cells require adrenal ...
Avishai-Eliner, S, Baram, TZ, Gerth, A, Hatalski, CG   +3 more
core   +1 more source

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton, Myrte Schoenmakers, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F. C. van Rossum   +4 more
wiley   +1 more source

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

Integrated Blood Pressure Control, 2013
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone was shown to be an extraordinarily effective ...
openaire   +4 more sources

Finerenone: a game changer for chronic kidney disease patients with type 2 diabetes

Journal of the Pakistan Medical Association
Dear Editor, Type 2 diabetes or (T2D) is characterized by the elevated blood glucose levels resulting from impaired beta-cell function and insulin resistance.
Fizzah Ikram Ul Haq, Aaitain Ikram Ul Haq   +1 more
doaj   +1 more source

Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Although the American Diabetes Association (ADA) recently established a diagnostic algorithm for the early detection of liver fibrosis among high‐risk individuals, its implications for chronic kidney disease (CKD) risk stratification remain unclear.
Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim   +4 more
wiley   +1 more source

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

Vascular Health and Risk Management, 2018
Mireille Fernet,1 Bruce Beckerman,2 Paula Abreu,2 Katharina Lins,3 John Vincent,2 Ellen Burgess4 1Department of Medical Affairs, Pfizer Canada Inc., Kirkland, QC, Canada; 2Department of Clinical Affairs, Pfizer Inc., New York, NY, USA; 3Department ...
Fernet M, Beckerman B, Abreu P, Lins K, Vincent J, Burgess E   +5 more
doaj  

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. [PDF]

, 2016
AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Claggett, Brian, Desai, Akshay S, Lefkowitz, Martin, McMurray, John JV, Packer, Milton, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators, Rouleau, Jean, Shi, Victor, Solomon, Scott D, Swedberg, Karl, Teerlink, John R, Vardeny, Orly, Zile, Michael R   +12 more
core   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Triptolide capsule enables proteinuria reduction and renal stabilization in advanced alport syndrome beyond standard therapy

Rheumatology &Autoimmunity, EarlyView.
Zhuo‐ran Song, Na Li, Yang Li, Hong Zhang, Xu‐jie Zhou   +4 more
wiley   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source